Although the SGLT2 inhibitor has been shown to inhibit renal glucose reabsorption, new mechanisms of this drug, such as its influence on inflammation, are thought-provoking and require further investigation [11, 12], especially for DN, which is a low inflammation disease. This evidence concerns the gene SLC5A2 and liver dysplastic nodule.